UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
2009, 1, ISBN 9781405168038, xii, 215
Book
American journal of hematology, ISSN 0361-8609, 07/2020, Volume 95, Issue 7, pp. 834 - 847
Life Sciences & Biomedicine | Hematology | Science & Technology | Meta-Analysis as Topic | Pandemics | COVID-19 Testing | Clinical Laboratory Techniques | Humans | Risk | Pneumonia, Viral - blood | Lymphopenia - etiology | Thrombophilia - etiology | Venous Thromboembolism - blood | COVID-19 | Venous Thromboembolism - prevention & control | SARS-CoV-2 | Blood Donors - supply & distribution | Ferritins - blood | Pneumonia, Viral - complications | Coronavirus Infections - blood | Betacoronavirus | Coronavirus Infections - complications | C-Reactive Protein - analysis | Thrombophilia - drug therapy | Cytokines - blood | Cytokine Release Syndrome - blood | Coronavirus Infections - diagnosis | Fibrin Fibrinogen Degradation Products - analysis | Anticoagulants - therapeutic use | Disseminated Intravascular Coagulation - blood | Venous Thromboembolism - etiology | Cytokine Release Syndrome - etiology | Thrombophilia - blood | Disseminated Intravascular Coagulation - etiology | Biomarkers | Blood Coagulation Tests | Pneumonia, Viral - diagnosis | Early Diagnosis | Thrombocytopenia | Vigilance | Degradation products | Blood & organ donations | Procalcitonin | Disseminated infection | Ferritin | Disseminated intravascular coagulation | Inflammation | Molecular weight | Hemopoiesis | Fibrin | Lymphopenia | Hemostasis | Cell number | Lymphocytes | Medical prognosis | Heparin | Thromboembolism | Index Medicus | Life Sciences | Human health and pathology
Journal Article
American journal of obstetrics and gynecology, ISSN 0002-9378, 2016, Volume 214, Issue 1, pp. 108.e1 - 108.e14
Obstetrics and Gynecology | angiogenic factors | systemic lupus erythematosus | preeclampsia | placental insufficiency | antiphospholipid antibodies | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Predictive Value of Tests | Pregnancy Trimester, First - blood | Antibodies, Antiphospholipid - blood | Prospective Studies | Humans | Heparin - therapeutic use | Lupus Erythematosus, Systemic - blood | Young Adult | Endoglin | Pregnancy Proteins - blood | Pregnancy, High-Risk | Lupus Erythematosus, Systemic - drug therapy | Adult | Female | Aspirin - therapeutic use | Pregnancy Trimester, Second - blood | Antiphospholipid Syndrome - blood | Fetal Growth Retardation - blood | Severity of Illness Index | Antiphospholipid Syndrome - drug therapy | Anticoagulants - therapeutic use | Receptors, Cell Surface - blood | Biomarkers - blood | Gestational Age | Pregnancy | Antigens, CD - blood | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Pre-Eclampsia - blood | Placenta Growth Factor | Vascular Endothelial Growth Factor Receptor-1 - blood | Pregnancy Outcome | Lupus | Prognosis | Systemic lupus erythematosus | Pregnant women | Growth | Patient outcomes | Analysis | Fetus | Antiphospholipid antibodies | Index Medicus | Abridged Index Medicus | Angiogenic factors
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 06/2014, Volume 111, Issue 6, pp. 1133 - 1140
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Anticoagulants - administration & dosage | Humans | Middle Aged | Prothrombin Time | Male | Reference Values | Thiophenes - administration & dosage | Morpholines - blood | Thiophenes - blood | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Venous Thromboembolism - blood | Rivaroxaban | Factor Xa Inhibitors - blood | Blood Coagulation Tests - instrumentation | Adult | Blood Coagulation Tests - methods | Female | Factor Xa Inhibitors - pharmacology | Cross-Sectional Studies | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Factor Xa - metabolism | Anticoagulants - blood | Atrial Fibrillation - blood | Blood Coagulation - drug effects | Point-of-Care Systems | Partial Thromboplastin Time | Anticoagulants - pharmacology | Aged | Whole Blood Coagulation Time
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 11/2015, Volume 13, Issue 11, pp. 1960 - 1967
critical care | thrombosis | point‐of‐care systems | platelet aggregation inhibitors | thoracic surgery | hemorrhage | Critical care | Point-of-care systems | Platelet aggregation inhibitors | Thoracic surgery | Hemorrhage | Thrombosis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Critical Care - methods | Point-of-Care Systems - economics | Humans | Critical Illness | Critical Care - economics | Drug Monitoring - methods | Postoperative Hemorrhage - blood | Blood Loss, Surgical | Blood Transfusion | Wounds and Injuries - therapy | Blood Coagulation Tests - economics | Thrombelastography - economics | Hemorrhage - etiology | Platelet Function Tests | Blood Coagulation Tests - methods | Postoperative Hemorrhage - therapy | Hemorrhage - therapy | Wounds and Injuries - blood | Blood Coagulation Disorders - etiology | Wounds and Injuries - complications | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Anticoagulants - blood | Randomized Controlled Trials as Topic | Cost-Benefit Analysis | Blood Coagulation Disorders - blood | Blood Coagulation Disorders - diagnosis | Disease Management | Hemorrhage - chemically induced | Biological products | Medical examination | Health aspects | Blood | Acute coronary syndromes | Mortality | Coagulation | Index Medicus
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 12/2010, Volume 104, Issue 6, pp. 1263 - 1271
prothrombin time | anti-Xa activity | Factor Xa inhibitor | international normalised ratio | Apixaban | New Technologies, Diagnostic Tools and Drugs | Anti-Xa activity | International normalised ratio | Prothrombin time | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Predictive Value of Tests | Pyrazoles - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Humans | Prothrombin Time | Anticoagulants - therapeutic use | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Pyridones - blood | Venous Thromboembolism - drug therapy | Anticoagulants - blood | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | International Normalized Ratio | Rivaroxaban | Blood Coagulation - drug effects | Pyrazoles - blood | Blood Coagulation Tests | Isoxazoles - blood | Pyridones - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
8.
Full Text
Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome
Thrombosis and haemostasis, ISSN 0340-6245, 2014, Volume 112, Issue 6, pp. 1277 - 1287
Cardiovascular Biology and Cell Signalling | Acute coronary syndrome | Platelets | Chemokines | Atherosclerosis | Neutrophils | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Heart | Hematologic and hematopoietic diseases | Atherosclerosis (general aspects, experimental research) | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Coronary heart disease | Blood and lymphatic vessels | Platelet diseases and coagulopathies | Predictive Value of Tests | Chemokines - blood | Blood Platelets - immunology | Prognosis | Prospective Studies | Humans | Middle Aged | Heparin - therapeutic use | Male | Case-Control Studies | Inflammation - blood | Chemokine CCL5 - blood | Dose-Response Relationship, Drug | Time Factors | Female | Inflammation - diagnosis | Antimicrobial Cationic Peptides - blood | Blood Platelets - drug effects | Neutrophils - metabolism | Carrier Proteins - blood | Neutrophils - drug effects | Inflammation Mediators - blood | Neutrophils - immunology | Acute Coronary Syndrome - immunology | Anticoagulants - therapeutic use | Linear Models | Inflammation - immunology | Biomarkers - blood | Chemokines - genetics | Disease Progression | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Platelet Count | Blood Platelets - metabolism | Blood Proteins | Acute Coronary Syndrome - diagnosis | Chemokine CCL5 - genetics | Aged | Polymorphism, Single Nucleotide | Acute Coronary Syndrome - genetics | Peroxidase - blood | atherosclerosis | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | chemokines | Klinisk medicin | neutrophils | platelets
Journal Article
08/2018, ISBN 0323462022, 1
eBook
Nature (London), ISSN 0028-0836, 05/2020, Volume 581, Issue 7808, pp. 250 - 250
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | COVID-19 | Fibrin Fibrinogen Degradation Products | Coronavirus Infections | Blood Coagulation Disorders - virology | SARS-CoV-2 | Coronavirus | Pandemics | Hospital Mortality | Humans | Betacoronavirus | Pneumonia, Viral | Prevention | Complications and side effects | Care and treatment | Patient outcomes | Anticoagulants (Medicine) | Dosage and administration | Diagnosis | Thrombosis | Blood clot | Coronaviruses | Blood vessels | Clinical trials | Infections | Health care facilities | t-Plasminogen activator | Blood | Endothelial cells | Blood clots | Severe acute respiratory syndrome coronavirus 2 | Proteins | Hospitals | Researchers | Dimers | Viral infections
Journal Article
British journal of haematology, ISSN 0007-1048, 12/2013, Volume 163, Issue 5, pp. 666 - 673
anti-Xa assay | PORTAL-VEIN THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | anticoagulants | antithrombin | CONSEQUENCES | LIVER-DISEASE | coagulation | HEMOSTASIS | cirrhosis | anti‐Xa assay | Anti-Xa assay | Anticoagulants | Cirrhosis | Antithrombin | Coagulation | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Tumors | Thiophenes - therapeutic use | Heparin, Low-Molecular-Weight - pharmacology | Polysaccharides - blood | Factor Xa Inhibitors | beta-Alanine - blood | Humans | Middle Aged | Heparin - therapeutic use | Male | Dabigatran | Drug Monitoring - methods | Morpholines - blood | Heparin, Low-Molecular-Weight - therapeutic use | Thiophenes - blood | Thrombophilia - etiology | Antithrombins - pharmacology | Rivaroxaban | Heparin, Low-Molecular-Weight - blood | Sensitivity and Specificity | beta-Alanine - pharmacology | Prothrombin - antagonists & inhibitors | Female | beta-Alanine - analogs & derivatives | Benzimidazoles - blood | Heparin - pharmacology | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Liver Cirrhosis - drug therapy | Liver Cirrhosis - complications | beta-Alanine - therapeutic use | False Negative Reactions | Morpholines - pharmacology | Thiophenes - pharmacology | Liver Cirrhosis - blood | Polysaccharides - pharmacology | Anticoagulants - blood | Diagnostic Tests, Routine | Blood Coagulation - drug effects | Thrombophilia - blood | Anticoagulants - pharmacology | Antithrombins - blood | Blood Coagulation Tests | Heparin - blood | Benzimidazoles - pharmacology | Liver cirrhosis | Anticoagulants (Medicine) | Index Medicus
Journal Article
Acta biomaterialia, ISSN 1742-7061, 08/2019, Volume 94, pp. 2 - 10
Medical devices | Anticoagulation | Thrombosis | Coagulation | Biomaterials | Engineering | Materials Science | Technology | Engineering, Biomedical | Materials Science, Biomaterials | Science & Technology | Prevention | Transluminal angioplasty | Medical equipment | Biological products | Coronary artery bypass | Atherosclerosis | Thromboembolism | Physiological apparatus | Adenosine triphosphatase | Anticoagulants | Surgical implants | Complications | Risk reduction | Blood | Clotting | Bleeding | Biomedical materials | Reviews | Medical electronics | Biocompatibility | Index Medicus
Journal Article